BackEagle Pharmaceuticals Overview

Eagle Pharmaceuticals Other Current Liabilities

Track Eagle Pharmaceuticals's other current liabilities ($2.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$2.46M
96.34% YoYΔ $-64.69M vs prior year quarter

Peer average / median

Loading

Eagle Pharmaceuticals Other Current Liabilities History

Loading

Eagle Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Eagle Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eagle Pharmaceuticals (EGRX) FAQ

As of the most recent data (June 2023), EGRX shows a other current liabilities of $2.5M. That compares with $67M in the prior-year period — down 96.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EGRX's other current liabilities is now $2.5M (was $67M) — a 96.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eagle Pharmaceuticals is outperforming or lagging.

Tracking EGRX's other current liabilities over time shows whether Eagle Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $2.5M That compares with $67M in the prior-year period — down 96.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Eagle Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $2.5M) with ownership activity and broader fundamentals.

Eagle Pharmaceuticals's other current liabilities is $2.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.